FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Bach-Yen Nguyen

Research Profile

Chemicals & Drugs

Disorders

HIV Infections

Living Beings

HIV-1

Procedures

Concepts & Ideas

Physiology

Viral Drug Resistance

Co-author Network

Publications

TOP 3
Jürgen K Rockstroh; Anthony Rodgers; Michael S Saag; Peter Sklar; Hedy Teppler; Monica L Walker; Hong Wan; Yazdan Yazdanpanah; Edwin DeJesus; Mark J DiNubile; Randi Leavitt; Jeffrey Lennox; Michael Miller; Bach-Yen Nguyen
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.
Eduardo Gotuzzo; Chengxing Lu; Martin Markowitz; Javier O Morales-Ramirez; Bach-Yen Nguyen; Guillermo Prada; Winai Ratanasuwan; Graham Smith; Kim M Strohmaier; Hedy Teppler; Sanhita Bhanja
Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004).
Edwin DeJesus; Mark J DiNubile; Adriano Lazzarin; Randi Leavitt; Jeffrey Lennox; Michael Miller; Bach-Yen Nguyen; Jürgen K Rockstroh; Anthony J Rodgers; Michael S Saag; Peter Sklar; Hedy Teppler; Monica L Walker; Hong Wan; Jing Zhao
Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Bach-Yen Nguyen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jürgen K Rockstroh; Anthony Rodgers; Michael S Saag; Peter Sklar; Hedy Teppler; Monica L Walker; Hong Wan; Yazdan Yazdanpanah; Edwin DeJesus; Mark J DiNubile; Randi Leavitt; Jeffrey Lennox; Michael Miller; Bach-Yen Nguyen
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.
Journal of acquired immune deficiency syndromes (1999) 2013;63(1):77-85.
2012: Eduardo Gotuzzo; Chengxing Lu; Martin Markowitz; Javier O Morales-Ramirez; Bach-Yen Nguyen; Guillermo Prada; Winai Ratanasuwan; Graham Smith; Kim M Strohmaier; Hedy Teppler; Sanhita Bhanja
Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004).
Journal of acquired immune deficiency syndromes (1999) 2012;61(1):73-7.
2012: Edwin DeJesus; Mark J DiNubile; Adriano Lazzarin; Randi Leavitt; Jeffrey Lennox; Michael Miller; Bach-Yen Nguyen; Jürgen K Rockstroh; Anthony J Rodgers; Michael S Saag; Peter Sklar; Hedy Teppler; Monica L Walker; Hong Wan; Jing Zhao
Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK.
HIV clinical trials 2012;13(4):228-32.
2012: Michael J Kozal; Max Lataillade; Randi Leavitt; Sergio Lupo; Marco Mancini; Cheryl McDonald; Donnie McGrath; Jean-Michel Molina; Bach-Yen Nguyen; Lisa Percival; Francois Raffi; Victoria Wirtz; Rong Yang; Jenny Zhang; Li Zhu; Dilek Arikan; Jorge Benetucci; Edwin DeJesus; Awny Farajallah
A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.
HIV clinical trials 2012;13(3):119-30.
2011: Jürgen K Rockstroh; Anthony Rodgers; Michael S Saag; Peter Sklar; Hedy Teppler; Monica L Walker; Hong Wan; Xia Xu; Jing Zhao; Edwin DeJesus; Mark J DiNubile; Adriano Lazzarin; Randi Leavitt; Jeffrey Lennox; Bach-Yen Nguyen
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2011;53(8):807-16.
2010: Jeffrey Lennox; Edwin Dejesus; Daniel S. Berger; Adriano Lazzarin; Richard B Pollard; Jose Valdez Ramalho Madruga; Jing Zhao; Hong Wan; Christopher L Gilbert; Hedy Teppler; Anthony Rodgers; Richard J O Barnard; Michael D Miller; Mark J DiNubile; Bach-Yen Nguyen; Randi Leavitt; Peter Sklar
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.
Journal of acquired immune deficiency syndromes (1999) 2010;55(1):39-48.
2010: Roy T Steigbigel; David A Cooper; Hedy Teppler; Joseph J Eron; Jose M Gatell; Princy N Kumar; Jurgen K Rockstroh; Mauro Schechter; Christine Katlama; Martin Markowitz; Patrick Yeni; Mona R Loutfy; Adriano Lazzarin; Jeffrey Lennox; Bonaventura Clotet; Jing Zhao; Hong Wan; Rand R Rhodes; Kim M Strohmaier; Richard J Barnard; Robin D Isaacs; Bach-Yen Nguyen
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010;50(4):605-12.
2010: Joseph J Eron; Benjamin Young; David A Cooper; Michael Youle; Edwin Dejesus; Jaime Andrade-Villanueva; Cassy Workman; Roberto Zajdenverg; Gerd Fätkenheuer; Daniel S. Berger; Princy N Kumar; Anthony Rodgers; Melissa A Shaughnessy; Monica L Walker; Richard J O Barnard; Michael D Miller; Mark J DiNubile; Bach-Yen Nguyen; Randi Leavitt; Xia Xu; Peter Sklar
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
Lancet 2010;375(9712):396-407.
2009: Martin Markowitz; Bach-Yen Nguyen; Eduardo Gotuzzo; Fernando Mendo; Winai Ratanasuwan; Colin Kovacs; Guillermo Prada; Javier O Morales-Ramirez; Clyde S Crumpacker; Robin D Isaacs; Havilland Campbell; Kim M Strohmaier; Hong Wan; Robert M Danovich; Hedy Teppler
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.
Journal of acquired immune deficiency syndromes (1999) 2009;52(3):350-6.
2009: Jeffrey Lennox; Edwin DeJesus; Adriano Lazzarin; Richard B Pollard; Jose Valdez Ramalho Madruga; Daniel S. Berger; Jing Zhao; Xia Xu; Angela Williams-Diaz; Anthony Rodgers; Richard J O Barnard; Michael D Miller; Mark J DiNubile; Bach-Yen Nguyen; Randi Leavitt; Peter Sklar
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Lancet 2009;374(9692):796-806.
2009: Marian Iwamoto; Larissa A Wenning; Bach-Yen Nguyen; Hedy Teppler; Allison R Moreau; Rand R Rhodes; William D Hanley; Bo Jin; Charlotte M Harvey; Sheila A Breidinger; Neal Azrolan; H Frank Farmer; Robin D Isaacs; Jeffery A Chodakewitz; Julie A Stone; John A Wagner
Effects of omeprazole on plasma levels of raltegravir.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;48(4):489-92.
2008: David A Cooper; Roy T Steigbigel; Jose M Gatell; Jurgen K Rockstroh; Christine Katlama; Patrick Yeni; Adriano Lazzarin; Bonaventura Clotet; Princy N Kumar; Joseph E Eron; Mauro Schechter; Martin Markowitz; Mona R Loutfy; Jeffrey Lennox; Jing Zhao; Joshua Chen; Desmond M Ryan; Rand R Rhodes; John A Killar; Lucinda R Gilde; Kim M Strohmaier; Anne R Meibohm; Michael D Miller; Daria J Hazuda; Michael L Nessly; Mark J DiNubile; Robin D Isaacs; Hedy Teppler; Bach-Yen Nguyen
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
The New England journal of medicine 2008;359(4):355-65.
2008: Roy T Steigbigel; David A Cooper; Princy N Kumar; Joseph E Eron; Mauro Schechter; Martin Markowitz; Mona R Loutfy; Jeffrey Lennox; Jose M Gatell; Jurgen K Rockstroh; Christine Katlama; Patrick Yeni; Adriano Lazzarin; Bonaventura Clotet; Jing Zhao; Joshua Chen; Desmond M Ryan; Rand R Rhodes; John A Killar; Lucinda R Gilde; Kim M Strohmaier; Anne R Meibohm; Michael D Miller; Daria J Hazuda; Michael L Nessly; Mark J DiNubile; Robin D Isaacs; Bach-Yen Nguyen; Hedy Teppler
Raltegravir with optimized background therapy for resistant HIV-1 infection.
The New England journal of medicine 2008;359(4):339-54.
2008: Lisa M Demeter; Victor DeGruttola; Stephanie Lustgarten; Daniel Bettendorf; Margaret A Fischl; Susan H Eshleman; William Spreen; Bach-Yen Nguyen; Christine E Koval; Joseph J Eron; Scott Hammer; Kathleen Squires
Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.
HIV clinical trials 2008;9(1):11-25.
2007: Martin Markowitz; Bach-Yen Nguyen; Eduardo Gotuzzo; Fernando Mendo; Winai Ratanasuwan; Colin Kovacs; Guillermo Prada; Javier O Morales-Ramirez; Clyde S Crumpacker; Robin D Isaacs; Lucinda R Gilde; Hong Wan; Michael D Miller; Larissa A Wenning; Hedy Teppler
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
Journal of acquired immune deficiency syndromes (1999) 2007;46(2):125-33.
2007: Beatriz Grinsztejn; Bach-Yen Nguyen; Christine Katlama; José M Gatell; Adriano Lazzarin; Daniel Vittecoq; Charles J Gonzalez; Joshua Chen; Charlotte M Harvey; Robin D Isaacs
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.
Lancet 2007;369(9569):1261-9.
2007: Jashvant D Unadkat; Diane Wara; Michael D Hughes; Anita A Mathias; Diane T Holland; Mary E Paul; James Connor; Sharon Huang; Bach-Yen Nguyen; D Heather Watts; Lynne M Mofenson; Elizabeth Smith; Paul Deutsch; Kathleen A Kaiser; Ruth E Tuomala
Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women.
Antimicrobial agents and chemotherapy 2007;51(2):783-6.
2006: Martin Markowitz; Javier O Morales-Ramirez; Bach-Yen Nguyen; Colin M Kovacs; Roy T Steigbigel; David A Cooper; Ralph Liporace; Robert Schwartz; Robin Isaacs; Lucinda R Gilde; Larissa Wenning; Jing Zhao; Hedy Teppler
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.
Journal of acquired immune deficiency syndromes (1999) 2006;43(5):509-15.
2006: B E de Pauw; Carole A Sable; THOMAS WALSH; Robert J Lupinacci; M R Bourque; B A Wise; Bach-Yen Nguyen; Mark J DiNubile; Hedy Teppler
Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study.
Transplant infectious disease : an official journal of the Transplantation Society 2006;8(1):31-7.
2004: Paul M Coplan; John R Cook; George W Carides; Joseph F Heyse; Albert W Wu; Scott M Hammer; Bach-Yen Nguyen; Anne R Meibohm; Mark J DiNubile
Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(3):426-33.
2004: Alina S Bergshoeff; Pieter L A Fraaij; Annemarie M C van Rossum; Gwenda Verweel; L H Wynne; G A Winchell; R Y Leavitt; Bach-Yen Nguyen; Ronald de Groot; David Burger
Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children.
Antimicrobial agents and chemotherapy 2004;48(5):1904-7.
2002: Carole A Sable; Bach-Yen Nguyen; Jeffrey A Chodakewitz; Mark J DiNubile
Safety and tolerability of caspofungin acetate in the treatment of fungal infections.
Transplant infectious disease : an official journal of the Transplantation Society 2002;4(1):25-30.